Deucravacitinib

ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter at the American Academy of Dermatology Annual Meeting.

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic arthritis, according to data published in Therapeutic Advances in Musculoskeletal Disease.

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, according to a poster presented at Maui Derm Hawaii 2025.

Deucravacitinib is superior to placebo for improving response across all domains of minimal disease activity criteria in patients with psoriatic arthritis at 16 weeks, according to data published in Rheumatology.

Ethan Craig, MD, spoke with Healio about treatment options coming up in the pipeline for psoriatic arthritis.

Deucravacitinib proved to be efficacious in the treatment of moderate to severe scalp psoriasis and less extensive overall psoriasis, according to two presentations at the European Academy of Dermatology and Venerology Congress.

In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.

A systemic review and meta-analysis revealed that higher initial glucocorticoid doses improved lupus nephritis treatment response but increased risks for serious infections and mortality.

Deucravacitinib is “very likely to be the best” targeted small-molecule drug for the treatment of systemic lupus erythematosus, according to data published in Arthritis Research & Therapy.

Patients with psoriatic arthritis who receive deucravacitinib report significant improvements in mental health, pain, fatigue and other outcomes vs. placebo, according to data published in Arthritis Care & Research.